"text","label","name","instanceType","description","uuid:ID","id"
"To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","","OBJ1","Objective","Main objective","8c8a35f1-3057-42e9-a7ec-5e04349c3c47","Objective_1"
"To document the safety profile of the xanomeline TTS.","","OBJ2","Objective","Safety","d3030927-ca1e-4f21-943c-4cd3faa065c5","Objective_2"
"To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","","OBJ3","Objective","Behaviour","fb9479d3-d487-4847-aab9-afaf142cf511","Objective_3"
